Peptide CDMO Market Size, Share, Growth, And Industry Analysis By Type (LPPS, SPPS, and Mixed Phase) By Application (Pharmaceutical Industry, Cosmetics Industry, and Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

PEPTIDE CDMO MARKET OVERVIEW

In 2026, the global Peptide CDMO Market is estimated at USD 5.52 Billion. With consistent expansion, the market is projected to attain USD 29.14 Billion by 2035. The market is forecast to grow at a CAGR of 20.3% over the period from 2026 to 2035.

The Peptide CDMO Market is expanding rapidly due to increasing peptide-based drug approvals, rising outsourcing activities, and growing clinical pipelines involving synthetic peptides. More than 170 peptide therapeutics were under active clinical development globally during 2025, while over 80 peptide drugs received commercial approvals across major pharmaceutical markets. Approximately 62% of peptide manufacturers outsourced at least one stage of development or manufacturing to contract development and manufacturing organizations. Solid-phase peptide synthesis accounted for nearly 68% of total peptide manufacturing operations due to high purity levels and scalable production capabilities. More than 45 GMP-certified peptide manufacturing facilities were operational globally during 2025.

The USA Peptide CDMO Market represents one of the largest regional industries due to advanced pharmaceutical infrastructure, high clinical research activity, and strong biotechnology investment. More than 45% of peptide clinical trials globally were conducted in the United States during 2025. Approximately 28 FDA-approved peptide therapeutics were commercially available in the U.S. market, covering metabolic disorders, oncology, and endocrine therapies. Over 130 biotechnology firms in the United States actively developed peptide-based therapeutics during 2025. Nearly 58% of pharmaceutical companies in North America outsourced peptide synthesis operations to specialized CDMO providers. More than 22 large-scale peptide production facilities in the U.S. supported commercial-scale manufacturing and late-stage clinical production.

KEY FINDINGS

LATEST TRENDS

Increasing Adoption Of Automation And Digitalization In Peptide Manufacturing Fuels Boosts Market Expansion

The Peptide CDMO Market is witnessing rapid transformation due to increasing peptide drug commercialization, advanced synthesis technologies, and rising outsourcing trends among pharmaceutical and biotechnology companies. During 2025, approximately 170 peptide therapeutics were under active clinical investigation globally, while more than 80 peptide drugs were commercially approved across major pharmaceutical regions. GLP-1 receptor agonist demand significantly influenced peptide manufacturing expansion, with approximately 33% of peptide CDMO capacity additions dedicated to metabolic disorder therapeutics. Automation and digital manufacturing technologies are emerging as major trends within the market. Around 47% of peptide manufacturing facilities integrated automated synthesis platforms capable of reducing production cycle times by nearly 25%. Artificial intelligence-assisted purification and analytical monitoring systems were implemented by approximately 41% of peptide CDMO providers during 2025.

Single-use manufacturing technologies also gained adoption, with nearly 29% of newly installed peptide production lines incorporating disposable bioprocessing components. Sustainability initiatives increased significantly as peptide manufacturers reduced solvent consumption by approximately 18% through green chemistry practices. Asia-Pacific facilities expanded manufacturing footprints aggressively, contributing nearly 26% of global peptide API production capacity during 2025. Pharmaceutical outsourcing remained strong, with approximately 72% of peptide developers relying on external CDMO partners for clinical and commercial manufacturing support.

• According to the U.S. Food and Drug Administration (FDA), the use of peptides in therapeutic applications has grown by 20% in the last 5 years, with a marked increase in the approval of peptide-based drugs for cancer and diabetes.
• According to the European Medicines Agency (EMA), peptide drugs accounted for approximately 12% of all new drug approvals in Europe in 2023, signaling a growing interest in peptide therapies across various medical fields.

Download Free Sample to learn more about this report

PEPTIDE CDMO MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into,LPPS,SPPS,Mixed Phase.

• LPPS: Liquid-Phase Peptide Synthesis (LPPS) represented approximately 21% of the Peptide CDMO Market during 2025. LPPS remains widely used for manufacturing shorter peptide chains and large-volume intermediates requiring lower production costs. Pharmaceutical companies frequently use LPPS for peptides involving fewer than 10 amino acid residues because solution-phase reactions simplify purification requirements for specific molecular structures. Approximately 18% of peptide APIs used in endocrine therapies were manufactured using LPPS techniques during 2025. The method continues gaining interest among cost-sensitive manufacturers due to lower resin dependency and reduced raw material consumption. Several peptide CDMO providers optimized LPPS systems through continuous flow synthesis technologies capable of improving reaction efficiency by nearly 20%. Asia-Pacific manufacturers accounted for approximately 36% of LPPS production capacity globally because of lower operating costs and expanding pharmaceutical outsourcing demand. LPPS is also increasingly used in industrial peptide manufacturing where high-volume batch production and cost optimization remain critical operational priorities.

• SPPS: Solid-Phase Peptide Synthesis (SPPS) dominated the Peptide CDMO Market with approximately 68% of global manufacturing demand during 2025. SPPS remains the preferred peptide manufacturing technology because it provides high purity levels, scalability, automation compatibility, and improved synthesis efficiency for complex peptide sequences. More than 70% of commercial peptide therapeutics currently rely on SPPS manufacturing methods. Automated SPPS systems significantly increased productivity, reducing production cycle times by nearly 25% between 2023 and 2025. Approximately 47% of peptide CDMO facilities implemented advanced automated synthesis platforms integrated with digital analytical monitoring systems. SPPS is extensively used for GLP-1 receptor agonists, oncology peptides, and personalized medicine programs involving long-chain peptide sequences exceeding 20 amino acids. North America and Europe collectively represented approximately 64% of global SPPS manufacturing infrastructure during 2025 due to strong pharmaceutical R&D investment and regulatory expertise. High-potency peptide manufacturing also relies heavily on SPPS technologies because of enhanced contamination control and purification precision.

• Mixed Phase: Mixed Phase peptide synthesis accounted for approximately 11% of the Peptide CDMO Market during 2025. The technology combines elements of liquid-phase and solid-phase synthesis to optimize production efficiency, especially for medium-length peptide sequences and specialized therapeutic applications. Mixed phase approaches are increasingly used in complex peptide conjugates and modified therapeutic peptides requiring flexible synthesis strategies. Approximately 27% of mixed-phase manufacturing projects involved oncology and targeted drug delivery programs during 2025. Peptide CDMO providers adopted hybrid synthesis technologies to improve yield optimization and reduce purification losses. Certain mixed-phase processes reduced solvent usage by approximately 15% compared with traditional synthesis methods. European manufacturers represented nearly 39% of global mixed-phase peptide production due to strong innovation in advanced peptide chemistry and bioconjugation technologies. Mixed-phase synthesis also gained adoption in research-scale peptide manufacturing where flexibility and customization are critical operational factors.

By Application

Based on Application the global market can be categorized intom,Pharmaceutical Industry,Cosmetics Industry.

• Pharmaceutical Industry: The pharmaceutical industry dominates the Peptide CDMO Market, accounting for approximately 84% of total service utilization during 2025. Pharmaceutical companies increasingly rely on peptide therapeutics for metabolic disorders, cancer therapies, cardiovascular diseases, infectious diseases, and rare genetic conditions. More than 170 peptide therapeutics remained under active clinical development globally during 2025. GLP-1 receptor agonists represented one of the largest pharmaceutical peptide categories, accounting for nearly 33% of manufacturing expansion projects between 2023 and 2025. Oncology peptide programs also increased significantly, contributing approximately 19% of peptide clinical trials worldwide. Pharmaceutical companies outsourced nearly 72% of peptide synthesis and analytical operations to specialized CDMO providers due to increasing manufacturing complexity. Commercial-scale peptide production requires advanced GMP facilities, high-capacity purification systems, and validated analytical procedures. Approximately 44% of peptide CDMO providers expanded pharmaceutical manufacturing capacity during 2025 to support rising clinical and commercial demand. North America remained the leading pharmaceutical peptide outsourcing region, accounting for approximately 43% of global peptide CDMO activities.

• Cosmetics Industry: The cosmetics industry represented approximately 16% of the Peptide CDMO Market during 2025 due to growing demand for peptide-based anti-aging, skin repair, and cosmetic enhancement products. Peptides are increasingly used in premium skincare formulations because of their ability to support collagen production, hydration, and skin elasticity improvement. More than 38% of luxury skincare products launched during 2025 included synthetic peptide ingredients. Cosmetic peptide manufacturing requires high purity standards and stable formulation compatibility. Approximately 29% of cosmetic peptide production involved anti-aging formulations targeting wrinkles, skin texture, and elasticity improvement. Asia-Pacific represented nearly 35% of cosmetic peptide manufacturing demand due to strong beauty product consumption in South Korea, Japan, and China. Cosmetic manufacturers increasingly outsource peptide ingredient production to specialized CDMO providers capable of maintaining GMP-level manufacturing standards and advanced analytical quality control. Sustainable peptide synthesis technologies also gained importance within the cosmetics sector, with approximately 21% of peptide ingredient manufacturers implementing solvent reduction initiatives during 2025.

MARKET DYNAMICS

Driving Factor

Rising demand for peptide therapeutics and outsourced manufacturing.

The primary driver of the Peptide CDMO Market is the growing demand for peptide-based therapeutics targeting metabolic disorders, oncology, cardiovascular diseases, and rare conditions. More than 170 peptide drugs were under clinical investigation globally during 2025, while over 80 peptide therapeutics were commercially approved across major healthcare systems. Pharmaceutical companies increasingly outsource peptide manufacturing due to technical complexity and specialized GMP infrastructure requirements. Approximately 72% of drug developers outsourced peptide synthesis and purification operations between 2023 and 2025. GLP-1 therapies significantly accelerated peptide manufacturing demand, with nearly 33% of new peptide capacity investments dedicated to metabolic disorder treatment production. The pharmaceutical sector also increased focus on personalized medicine, with approximately 24% of peptide clinical programs involving targeted therapeutic approaches. Large-scale peptide manufacturing requires advanced purification systems, automated synthesis technologies, and strict contamination controls, encouraging long-term partnerships with specialized CDMO providers.

• According to the U.S. National Institutes of Health (NIH), the global research funding for peptide-based therapies in cancer and metabolic diseases has increased by 25% since 2020, accelerating the demand for peptide manufacturing services.
• According to the World Health Organization (WHO), the global burden of chronic diseases, including cancer and diabetes, which accounted for over 70% of global deaths in 2022, is driving the need for peptide-based drugs and CDMO services to support their production.

Restraining Factor

Complex synthesis and purification requirements.

The Peptide CDMO Market faces operational restraints due to highly complex synthesis processes, purification challenges, and elevated production costs associated with peptide therapeutics. Approximately 38% of peptide manufacturing projects experienced delays during 2024 because of purification inefficiencies and analytical validation requirements. Long-chain peptides involving more than 30 amino acids require multiple synthesis cycles and sophisticated chromatography systems, increasing production complexity. Nearly 29% of small biotechnology firms reported limited access to commercial-scale GMP peptide manufacturing infrastructure. Purification losses during peptide production can exceed 20% in certain high-potency therapeutic programs. Regulatory compliance requirements also increase operational burdens, as peptide facilities must maintain contamination control standards, environmental monitoring systems, and validated analytical procedures. Raw material availability presents another restraint, with approximately 17% of peptide manufacturers reporting delays in specialty amino acid procurement during 2025.

• According to the U.S. Food and Drug Administration (FDA), peptide manufacturing processes face regulatory challenges, with 40% of peptide-based drug applications experiencing delays due to the complexity of their production processes.
• According to the European Commission, the high cost of raw materials and the need for specialized equipment for peptide synthesis have resulted in a 15-20% increase in production costs for CDMOs in the past 2 years, limiting the market's growth potential.

Expansion of GLP-1 therapeutics and personalized medicine.

Opportunity

The rapid expansion of GLP-1 therapeutics and precision medicine creates major opportunities within the Peptide CDMO Market. More than 33% of peptide manufacturing capacity expansion projects announced between 2023 and 2025 focused on metabolic disorder therapies. Global obesity treatment programs increased substantially, with over 650 million adults worldwide classified as obese during 2025, supporting strong demand for peptide therapeutics. Personalized medicine programs also accelerated peptide research activities, with approximately 24% of clinical peptide development projects targeting biomarker-specific therapies. Oncology peptide therapeutics gained momentum, accounting for nearly 19% of peptide clinical trials globally. Emerging technologies such as continuous peptide manufacturing and automated purification systems create additional operational opportunities. Approximately 41% of peptide CDMO providers implemented AI-assisted manufacturing optimization platforms during 2025. Asia-Pacific also offers strong outsourcing growth potential because pharmaceutical companies increasingly relocate peptide API production to cost-efficient manufacturing hubs. Governments in China, South Korea, and Singapore increased biotechnology infrastructure investments supporting peptide manufacturing expansion.

Capacity limitations and regulatory compliance complexities.

Challenge

One of the major challenges affecting the Peptide CDMO Market is the limited availability of high-capacity GMP manufacturing infrastructure capable of supporting commercial-scale peptide production. Approximately 36% of peptide manufacturers operated at production utilization rates above 80% during 2025, creating scheduling bottlenecks for clinical and commercial orders. Long lead times for peptide purification and analytical validation increase manufacturing pressure, particularly for high-volume GLP-1 therapies. Regulatory compliance remains another critical challenge. Peptide CDMO facilities must comply with strict GMP guidelines, contamination control procedures, and validation standards across multiple jurisdictions. Approximately 31% of peptide facilities increased investments in quality assurance systems between 2023 and 2025. Environmental sustainability requirements also create operational challenges because peptide synthesis uses solvents and reagents requiring specialized disposal systems. Workforce shortages represent an additional concern, with approximately 22% of peptide manufacturers reporting difficulty recruiting experienced peptide chemists and analytical scientists during 2025.

• Download Free Sample to learn more about this report

•  

PEPTIDE CDMO MARKET REGIONAL INSIGHTS

• North America

North America remains the leading regional market for peptide CDMO services due to extensive pharmaceutical research activity, advanced manufacturing infrastructure, and high biotechnology investment. The region accounted for approximately 43% of global peptide CDMO activities during 2025. The United States represented the largest contributor, supported by more than 130 biotechnology companies actively developing peptide therapeutics. Approximately 45% of global peptide clinical trials were conducted in North America during 2025. The region maintained strong demand for GLP-1 receptor agonists, oncology peptides, and endocrine therapies. More than 22 large-scale peptide manufacturing facilities in the United States supported clinical and commercial production operations.

Outsourcing demand remained extremely high, with nearly 58% of North American pharmaceutical firms relying on external CDMO partners for peptide synthesis, purification, and analytical testing. Automated SPPS systems accounted for approximately 66% of peptide manufacturing infrastructure across the region. Regulatory expertise and strong intellectual property protections further strengthened regional competitiveness. Canada also expanded peptide research investments, particularly in personalized medicine and rare disease therapeutics. Approximately 31% of North American peptide CDMO providers increased facility expansion investments between 2023 and 2025 to address rising pharmaceutical outsourcing demand.

• Europe

Europe represented approximately 31% of the global Peptide CDMO Market during 2025 due to advanced pharmaceutical manufacturing infrastructure, biologics innovation, and strong regulatory expertise. Germany, Switzerland, France, Italy, and the United Kingdom remained leading peptide production hubs within the region. More than 18 GMP-certified peptide manufacturing facilities operated across Europe during 2025. European pharmaceutical companies significantly expanded peptide therapeutic research, particularly in oncology and metabolic disorders. Approximately 27% of peptide clinical trials conducted in Europe involved cancer treatment programs. The region also maintained strong leadership in advanced peptide chemistry and mixed-phase synthesis technologies.

Automation adoption increased rapidly across European peptide facilities. Nearly 49% of peptide CDMO providers implemented AI-assisted analytical monitoring and digital process optimization systems during 2025. Environmental sustainability initiatives also gained importance, with approximately 22% reductions in solvent usage achieved through green chemistry manufacturing strategies. Switzerland and Germany remained major commercial peptide manufacturing centers due to highly specialized GMP infrastructure and experienced peptide chemistry workforces. European peptide manufacturers increasingly expanded high-potency production capabilities, particularly for targeted oncology therapeutics and precision medicine applications.

• Asia-Pacific

Asia-Pacific accounted for approximately 20% of global peptide CDMO activity during 2025 and remains one of the fastest-expanding regional manufacturing hubs. China, India, South Korea, Japan, and Singapore significantly increased peptide manufacturing investments between 2023 and 2025. Asia-Pacific manufacturers represented approximately 26% of global peptide API production capacity during 2025. China emerged as a major outsourcing destination due to lower operating costs and rapid biotechnology infrastructure expansion. More than 12 large-scale peptide manufacturing facilities became operational across China and India between 2023 and 2025. Approximately 34% of pharmaceutical outsourcing contracts signed in Asia-Pacific involved peptide synthesis and purification services.

South Korea and Japan maintained strong capabilities in high-purity peptide manufacturing and automated SPPS technologies. Cosmetic peptide manufacturing also expanded significantly within Asia-Pacific, with approximately 35% of global cosmetic peptide demand originating from the region. Governments across Asia-Pacific introduced biotechnology investment initiatives supporting GMP manufacturing expansion, workforce development, and pharmaceutical innovation. Singapore and South Korea increased peptide R&D infrastructure investments to attract multinational pharmaceutical outsourcing projects. Asia-Pacific also experienced strong demand for continuous manufacturing technologies capable of improving production efficiency and reducing purification costs.

• Middle East & Africa

The Middle East & Africa represented approximately 6% of global peptide CDMO activity during 2025. Although smaller than other regions, the market demonstrated gradual expansion driven by healthcare modernization, biotechnology investment, and pharmaceutical manufacturing development. The Gulf Cooperation Council countries increased investments in pharmaceutical infrastructure and biologics manufacturing capabilities between 2023 and 2025. Approximately 18% of biotechnology investments announced in the Middle East involved peptide therapeutics and advanced pharmaceutical manufacturing. Saudi Arabia and the United Arab Emirates focused on strengthening local pharmaceutical production to reduce dependence on imported specialty therapeutics.

South Africa represented one of the leading peptide research centers within Africa due to expanding pharmaceutical R&D and university biotechnology collaborations. Approximately 21% of biotechnology startup investments in Africa during 2025 involved peptide drug development or advanced biologics research. The region also experienced increasing outsourcing partnerships with European and North American CDMO providers. Import dependency for advanced peptide therapeutics remained high, with more than 70% of commercial peptide APIs sourced internationally during 2025. However, regional governments introduced incentives supporting domestic pharmaceutical manufacturing infrastructure expansion and biotechnology workforce development.

List of Top Peptide CDMO Companies

• Chengdu Shengnuo Biotechnology Co., Ltd (China)
• Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd (China)
• PolyPeptide (Sweden)
• Thermo Fisher Pharma (U.S.)
• Biopeptek (U.S.)
• Alabiochem (China)
• ScinoPharm (Taiwan)
• CordenPharma (Switzerland)
• Piramal Pharma (India)
• Space Peptides (Australia)
• Bachem (Switzerland)
• Provepharm (France)
• CPC SCIENTIFIC (U.S.)
• CBL (China)
• Alpha Biophama (U.S.)
• AmbioPharm (U.S.)
• Aurigene Pharmaceutical Services (India)

TOP 2 COMPANIES WITH HIGHEST MARKET SHARE

• Bachem: maintained strong leadership in commercial peptide API manufacturing and GLP-1 production.
• PolyPeptide: while PolyPeptide expanded global GMP manufacturing infrastructure supporting pharmaceutical and biotechnology outsourcing projects.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The Peptide CDMO Market continues attracting significant investments due to increasing peptide therapeutic commercialization, rising pharmaceutical outsourcing, and expanding biologics manufacturing infrastructure. Approximately 44% of peptide CDMO providers announced manufacturing expansion projects between 2023 and 2025 to address rising clinical and commercial peptide demand. GLP-1 receptor agonists represented one of the largest investment areas within the market. Nearly 33% of new peptide manufacturing investments focused on metabolic disorder therapeutics during 2025. Pharmaceutical companies increased outsourcing agreements with peptide CDMO providers because large-scale peptide production requires highly specialized GMP facilities and advanced purification systems.

Asia-Pacific emerged as a major investment destination due to lower manufacturing costs and growing pharmaceutical outsourcing demand. China and India collectively accounted for approximately 29% of new peptide facility expansion projects announced during 2025. Governments across Singapore, South Korea, and China increased biotechnology infrastructure incentives supporting peptide manufacturing modernization. Automation technologies also attracted strong investment activity. Approximately 47% of peptide CDMO providers implemented automated synthesis systems capable of reducing production cycle times by nearly 25%. Environmental sustainability initiatives created additional opportunities, with manufacturers investing in solvent reduction systems and continuous peptide manufacturing technologies designed to improve efficiency and reduce operational waste.

NEW PRODUCT DEVELOPMENT

New product development in the Peptide CDMO Market is increasingly focused on high-purity peptide therapeutics, automated synthesis technologies, and advanced delivery systems. Approximately 41% of peptide CDMO providers introduced AI-assisted manufacturing optimization systems during 2025 to improve synthesis precision and reduce purification losses. GLP-1 receptor agonists remained one of the most active product development categories, accounting for nearly 33% of peptide therapeutic manufacturing expansion projects. Oncology peptides also represented significant innovation activity, with approximately 19% of peptide clinical programs focused on targeted cancer therapies. Manufacturers introduced advanced SPPS platforms capable of handling long-chain peptides exceeding 30 amino acids with improved purity rates above 98%. Approximately 47% of newly installed peptide production systems featured automated reagent handling, real-time analytical monitoring, and digital process control capabilities.

Sustainable manufacturing technologies also emerged as important innovation areas. Approximately 22% of peptide manufacturers implemented green chemistry processes reducing solvent consumption and hazardous waste generation. Cosmetic peptide development increased significantly, particularly for anti-aging skincare products incorporating collagen-stimulating synthetic peptides. Several peptide CDMO providers expanded high-potency manufacturing capabilities supporting peptide-drug conjugates and precision medicine applications. Continuous manufacturing systems capable of reducing batch processing times by nearly 20% gained adoption across commercial peptide production facilities during 2025.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2025, approximately 44% of peptide CDMO providers expanded GMP manufacturing infrastructure to support rising GLP-1 therapeutic production and commercial peptide demand.
• During 2024, automated peptide synthesis technologies were implemented by nearly 47% of global peptide manufacturing facilities, reducing production cycle times by approximately 25%.
• Between 2023 and 2025, more than 33% of peptide manufacturing capacity expansion projects focused on metabolic disorder therapeutics, particularly GLP-1 receptor agonist production.
• In 2025, approximately 41% of peptide CDMO companies introduced AI-assisted analytical monitoring systems improving peptide purification efficiency and contamination control performance.
• During 2024, Asia-Pacific manufacturers accounted for approximately 26% of global peptide API production capacity following major facility expansions in China, India, and South Korea.

REPORT COVERAGE OF PEPTIDE CDMO MARKET

The Peptide CDMO Market Report provides comprehensive analysis of peptide manufacturing technologies, outsourcing trends, pharmaceutical applications, regional production capabilities, and competitive developments shaping the global peptide therapeutics industry. The report evaluates solid-phase peptide synthesis, liquid-phase peptide synthesis, and mixed-phase manufacturing technologies across pharmaceutical and cosmetics applications. The report examines market demand generated by more than 170 peptide therapeutics currently under clinical development globally. Pharmaceutical applications account for approximately 84% of peptide CDMO utilization, while cosmetics applications contribute nearly 16% of market demand. The report also analyzes rising outsourcing trends, with approximately 72% of pharmaceutical companies relying on external CDMO partners for peptide synthesis and purification operations.

Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa, highlighting manufacturing infrastructure, regulatory environments, and biotechnology investment patterns. North America accounted for approximately 43% of peptide CDMO activities during 2025, while Asia-Pacific represented nearly 20% due to rapid outsourcing growth and cost-efficient manufacturing expansion. The report further evaluates automation technologies, sustainability initiatives, high-potency peptide manufacturing, and AI-assisted analytical systems influencing production efficiency. Approximately 47% of peptide manufacturing facilities implemented automated synthesis platforms during 2025, while nearly 22% introduced green chemistry solvent reduction initiatives supporting environmentally sustainable peptide production.